Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Exelixis, Inc.

SG&A Expenses: Bristol-Myers Squibb vs. Exelixis, 2014-2023

__timestampBristol-Myers Squibb CompanyExelixis, Inc.
Wednesday, January 1, 2014569900000050829000
Thursday, January 1, 2015500100000057305000
Friday, January 1, 20165002000000116145000
Sunday, January 1, 20174849000000159362000
Monday, January 1, 20184551000000206366000
Tuesday, January 1, 20194871000000228244000
Wednesday, January 1, 20207661000000293355000
Friday, January 1, 20217690000000401715000
Saturday, January 1, 20227814000000459856000
Sunday, January 1, 20237772000000542705000
Monday, January 1, 20248414000000492128000
Loading chart...

Data in motion

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of major players is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and Exelixis, Inc. from 2014 to 2023. Bristol-Myers Squibb, a giant in the industry, consistently outspent Exelixis, with its SG&A expenses peaking in 2022 at approximately 7.8 billion dollars. This represents a 37% increase from its 2014 expenses. In contrast, Exelixis, a smaller biotech firm, saw its SG&A expenses grow by over 900% during the same period, reaching around 543 million dollars in 2023. This dramatic rise reflects Exelixis's aggressive expansion and investment in its operations. The data highlights the contrasting scales and growth strategies of these two companies, offering insights into their financial priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025